Lead Product(s) : CCX140
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The LUMINA-1 trial tested CCX140 in primary FSGS subjects. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
Product Name : CCX140
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : CCX140
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
